Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...

Increasing travel burden was associated with lower surgery likelihood, with a 6% odds reduction per additional travel hour ...

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy ...

Executive and administrative shifts around CDC recommendations have generated confusion that clinicians report is being ...

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of ...

Body mass index (BMI) is recorded at nearly every clinical encounter, yet patients with obesity routinely reach specialty care only after years of untreated disease. Clinicians who treat them ...

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's ...

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that ...

In 'Empowering Community Oncology: Infrastructure Investments for Bringing Novel RRFL Therapies to Patients,' Tara Graff, DO, ...

Zanubrutinib may provide longer progression-free survival (PFS) than fludarabine, cyclophosphamide, and rituximab (FCR) in ...